What is the clinical importance of RAS mutations in treatment of metastatic CRC?
The RAS mutation, it predicts resistance to EGFR antibody, and that makes sense because we realize that the receptor signals through RAS to actually affect growth of the cancer cell. So whereas the antibody that hits the receptor might impair the growth of the cell in a RAS wild type where the signaling pathway is appropriately functioning, if you have the mutation in that downstream event of RAS, which by the way that mutation turns the gene on permanently, so because that downstream event is switched on no matter what, whether you affect the upstream receptor with the antibody or not, you realize the antibody won't work. Even if you turn the receptor off, the next step is turned on by the mutation.
Unresectable Colon Cancer: Case 2
52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More